Sphingolipid metabolism and leukemia: A potential for novel therapeutic approaches

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 863-881

  Burns, Tara Ann ^a   Luberto, Chiara ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ALL; AML; Ceramide; CLL; CML; Leukemia; LGL; Sphingolipids; Sphingosine 1 phosphate

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; BML 258; CARBOPLATIN; CERAMIDE; CYTARABINE; DACINOSTAT; DACTINOMYCIN; DIPHTHERIA TOXIN 388 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION PROTEIN; DOXORUBICIN; ETOPOSIDE; FINGOLIMOD; GLYCEROLIPID; GW 1843; HYDROXYUREA; IMATINIB; SPHINGOLIPID; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; LEUKEMIA; LIPID METABOLISM; LIVER TOXICITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 80054081420     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655140     Document Type: Review

References (285)

1. Hannun, Y.A.; Obeid, L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell. Biol., 2008, 9(2), 139-150.
2. Thudichum, J.L.W. A treatise on the chemical constitution of the brain; Bailliere, Tindall, and Cox: London, 1884.
3. Futerman, A.H.; Riezman, H. The ins and outs of sphingolipid synthesis. Trends Cell. Biol., 2005, 15(6), 312-318.
4. Gulbins, E. Highlight: sphingolipids - signals and disease. Biol. Chem., 2008, 389(11), 1347-1348.
5. Maceyka, M.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J. Lipid Res., 2009, 50 Suppl, S272-S276.
6. Merrill, A.H., Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem., 2002, 277(29), 25843-25846.
7. Merrill, A.H., Jr.; Wang, M.D.; Park, M.; Sullards, M.C. (Glyco)sphingolipidology: an amazing challenge and opportunity for systems biology. Trends Biochem. Sci., 2007, 32(10), 457-468.
8. Sabourdy, F.; Kedjouar, B.; Sorli, S.C.; Colie, S.; Milhas, D.; Salma, Y.; Levade, T. Functions of sphingolipid metabolism in mammals--lessons from genetic defects. Biochim. Biophys. Acta, 2008, 1781(4), 145-183.
9. Kitatani, K.; Idkowiak-Baldys, J.; Hannun, Y.A. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal., 2008, 20(6), 1010-1018.
10. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; Merrill, A.H., Jr.; Milstien, S.; Spiegel, S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280(44), 37118-37129.
11. Serra, M.; Saba, J.D. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv. Enzyme Regul., 2010, 50(1), 349-362.
12. El Bawab, S.; Roddy, P.; Qian, T.; Bielawska, A.; Lemasters, J.J.; Hannun, Y.A. Molecular cloning and characterization of a human mitochondrial ceramidase. J. Biol. Chem., 2000, 275(28), 21508-21513.
13. Mao, C.; Xu, R.; Bielawska, A.; Obeid, L.M. Cloning of an alkaline ceramidase from Saccharomyces cerevisiae. An enzyme with reverse (CoA-independent) ceramide synthase activity. J. Biol. Chem., 2000, 275(10), 6876-6884.
14. Mao, C.; Xu, R.; Bielawska, A.; Szulc, Z.M.; Obeid, L.M. Cloning and characterization of a Saccharomyces cerevisiae alkaline ceramidase with specificity for dihydroceramide. J. Biol. Chem., 2000, 275(40), 31369-31378.
15. Ogretmen, B.; Hannun, Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer, 2004, 4(8), 604-616.
16. Mao, C.; Obeid, L.M. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim. Biophys. Acta, 2008, 1781(9), 424-434.
17. Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets, 2008, 9(8), 662-673.
18. Hannun, Y.A.; Luberto, C.; Argraves, K.M. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry, 2001, 40(16), 4893-4903.
19. Okazaki, T.; Bell, R.M.; Hannun, Y.A. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem., 1989, 264(32), 19076-19080.
20. Okazaki, T.; Bielawska, A.; Bell, R.M.; Hannun, Y.A. Role of ceramide as a lipid mediator of 1 alpha, 25-dihydroxyvitamin D3- induced HL-60 cell differentiation. J. Biol. Chem., 1990, 265(26), 15823-15831.
21. Obeid, L.M.; Linardic, C.M.; Karolak, L.A.; Hannun, Y.A. Programmed cell death induced by ceramide. Science, 1993, 259(5102), 1769-1771.
22. Futerman, A.H. Ceramide Signaling. Plenum Publishers: New York, 2002.
23. Kolesnick, R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest., 2002, 110(1), 3-8.
24. Lavieu, G.; Scarlatti, F.; Sala, G.; Levade, T.; Ghidoni, R.; Botti, J.; Codogno, P. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy, 2007, 3(1), 45-47.
25. Merrill, A.H., Jr.; Jones, D.D. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim. Biophys. Acta, 1990, 1044(1), 1-12.
26. Ryland, L.K.; Fox, T.E.; Liu, X.; Loughran, T.P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther., 2011, 11(2), 138-149.
27. Zhang, Y.; Li, X.; Becker, K.A.; Gulbins, E. Ceramide-enriched membrane domains--structure and function. Biochim. Biophys. Acta, 2009, 1788(1), 178-183.
28. Seumois, G.; Fillet, M.; Gillet, L.; Faccinetto, C.; Desmet, C.; Francois, C.; Dewals, B.; Oury, C.; Vanderplasschen, A.; Lekeux, P.; Bureau, F. De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J. Leukoc. Biol., 2007, 81(6), 1477-1486.
29. Farrell, A.M.; Uchida, Y.; Nagiec, M.M.; Harris, I.R.; Dickson, R.C.; Elias, P.M.; Holleran, W.M. UVB irradiation up-regulates serine palmitoyltransferase in cultured human keratinocytes. J. Lipid Res., 1998, 39(10), 2031-2038.
30. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicininduced apoptosis: an alternative mechanism for generating death signals. Cell, 1995, 82(3), 405-414.
31. Perry, D.K.; Carton, J.; Shah, A.K.; Meredith, F.; Uhlinger, D.J.; Hannun, Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem., 2000, 275(12), 9078-9084.
32. Senkal, C.E.; Ponnusamy, S.; Rossi, M.J.; Bialewski, J.; Sinha, D.; Jiang, J.C.; Jazwinski, S.M.; Hannun, Y.A.; Ogretmen, B. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol. Cancer Ther., 2007, 6(2), 712-722.
33. Shirakabe, K.; Yamaguchi, K.; Shibuya, H.; Irie, K.; Matsuda, S.; Moriguchi, T.; Gotoh, Y.; Matsumoto, K.; Nishida, E. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem., 1997, 272(13), 8141-8144.
34. Jenkins, G.M. The emerging role for sphingolipids in the eukaryotic heat shock response. Cell. Mol. Life Sci., 2003, 60(4), 701-710.
35. Karakashian, A.A.; Giltiay, N.V.; Smith, G.M.; Nikolova- Karakashian, M.N. Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation. FASEB. J., 2004, 18(9), 968-970.
36. Jin, J.; Hou, Q.; Mullen, T.D.; Zeidan, Y.H.; Bielawski, J.; Kraveka, J.M.; Bielawska, A.; Obeid, L.M.; Hannun, Y.A.; Hsu, Y.T. Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells. J. Biol. Chem., 2008, 283(39), 26509-26517.
37. Watson, M.L.; Coghlan, M.; Hundal, H.S. Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-induced insulin resistance in rat skeletal muscle cells. Biochem. J., 2009, 417(3), 791-801.
38. Chavez, J.A.; Summers, S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys., 2003, 419(2), 101-109.
39. Lahiri, S.; Futerman, A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci., 2007, 64(17), 2270-2284.
40. Ito, Y.; Sato, S.; Ohashi, T.; Nakayama, S.; Shimokata, K.; Kume, H. Reduction of airway anion secretion via CFTR in sphingomyelin pathway. Biochem. Biophys. Res. Commun., 2004, 324(2), 901-908.
41. Vilela, R.M.; Lands, L.C.; Meehan, B.; Kubow, S. Inhibition of IL- 8 release from CFTR-deficient lung epithelial cells following pretreatment with fenretinide. Int. Immunopharmacol., 2006, 6(11), 1651-1664.
42. Summers, S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res., 2006, 45(1), 42-72.
43. Petrache, I.; Natarajan, V.; Zhen, L.; Medler, T.R.; Richter, A.T.; Cho, C.; Hubbard, W.C.; Berdyshev, E.V.; Tuder, R.M. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat. Med., 2005, 11(5), 491-498.
44. Petrache, I.; Natarajan, V.; Zhen, L.; Medler, T.R.; Richter, A.; Berdyshev, E.V.; Tuder, R.M. Ceramide causes pulmonary cell apoptosis and emphysema: a role for sphingolipid homeostasis in the maintenance of alveolar cells. Proc. Am. Thorac. Soc., 2006, 3(6), 510.
45. Yoo, H.S.; Norred, W.P.; Wang, E.; Merrill, A.H., Jr.; Riley, R.T. Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. Toxicol. Appl. Pharmacol., 1992, 114(1), 9-15.
46. Wu, W.I.; McDonough, V.M.; Nickels, J.T., Jr.; Ko, J.; Fischl, A.S.; Vales, T.R.; Merrill, A.H., Jr.; Carman, G.M. Regulation of lipid biosynthesis in Saccharomyces cerevisiae by fumonisin B1. J. Biol. Chem., 1995, 270(22), 13171-13178.
47. Nilsson, A. The presence of spingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim. Biophys. Acta., 1969, 176(2), 339-347.
48. Duan, R.D.; Bergman, T.; Xu, N.; Wu, J.; Cheng, Y.; Duan, J.; Nelander, S.; Palmberg, C.; Nilsson, A. Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J. Biol. Chem., 2003, 278(40), 38528-38536.
49. Wu, J.; Cheng, Y.; Palmberg, C.; Bergman, T.; Nilsson, A.; Duan, R.D. Cloning of alkaline sphingomyelinase from rat intestinal mucosa and adjusting of the hypothetical protein XP_221184 in GenBank. Biochim. Biophys. Acta, 2005, 1687(1-3), 94-102.
50. Krut, O.; Wiegmann, K.; Kashkar, H.; Yazdanpanah, B.; Kronke, M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J. Biol. Chem., 2006, 281(19), 13784-13793.
51. Wu, B.X.; Rajagopalan, V.; Roddy, P.L.; Clarke, C.J.; Hannun, Y.A. Identification and characterization of murine mitochondriaassociated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5. J. Biol. Chem., 2010, 285(23), 17993-18002.
52. Tomiuk, S.; Hofmann, K.; Nix, M.; Zumbansen, M.; Stoffel, W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc. Natl. Acad. Sci. U S A, 1998, 95(7), 3638-3643.
53. Hofmann, K.; Tomiuk, S.; Wolff, G.; Stoffel, W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc. Natl. Acad. Sci. U S A, 2000, 97(11), 5895-5900.
54. Schuchman, E.H. Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. F.E.B.S. Lett., 2010, 584(9), 1895-1900.
55. Sawai, H.; Domae, N.; Nagan, N.; Hannun, Y.A. Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C. J. Biol. Chem., 1999, 274(53), 38131-38139.
56. Horinouchi, K.; Erlich, S.; Perl, D.P.; Ferlinz, K.; Bisgaier, C.L.; Sandhoff, K.; Desnick, R.J.; Stewart, C.L.; Schuchman, E.H. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet., 1995, 10(3), 288-293.
57. Brady, R.O.; Kanfer, J.N.; Mock, M.B.; Fredrickson, D.S. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc. Natl. Acad. Sci. U S A., 1966, 55(2), 366-369.
58. Becker, K.A.; Grassme, H.; Zhang, Y.; Gulbins, E. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell. Physiol. Biochem., 2010, 26(1), 57-66.
59. Grassme, H.; Becker, K.A.; Zhang, Y.; Gulbins, E. Ceramide in bacterial infections and cystic fibrosis. Biol. Chem., 2008, 389(11), 1371-1379.
60. Utermohlen, O.; Herz, J.; Schramm, M.; Kronke, M. Fusogenicity of membranes: the impact of acid sphingomyelinase on innate immune responses. Immunobiology, 2008, 213(3-4), 307-314.
61. Schramm, M.; Herz, J.; Haas, A.; Kronke, M.; Utermohlen, O. Acid sphingomyelinase is required for efficient phago-lysosomal fusion. Cell. Microbiol., 2008, 10(9), 1839-1853.
62. Ng, C.G.; Griffin, D.E. Acid sphingomyelinase deficiency increases susceptibility to fatal alphavirus encephalomyelitis. J. Virol., 2006, 80(22), 10989-10999.
63. Zeidan, Y.H.; Wu, B.X.; Jenkins, R.W.; Obeid, L.M.; Hannun, Y.A. A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. FASEB J., 2008, 22(1), 183-193.
64. Santana, P.; Pena, L.A.; Haimovitz-Friedman, A.; Martin, S.; Green, D.; McLoughlin, M.; Cordon-Cardo, C.; Schuchman, E.H.; Fuks, Z.; Kolesnick, R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell, 1996, 86(2), 189-199.
65. Cifone, M.G.; De Maria, R.; Roncaioli, P.; Rippo, M.R.; Azuma, M.; Lanier, L.L.; Santoni, A.; Testi, R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J. Exp. Med., 1994, 180(4), 1547-1552.
66. Gulbins, E.; Bissonnette, R.; Mahboubi, A.; Martin, S.; Nishioka, W.; Brunner, T.; Baier, G.; Baier-Bitterlich, G.; Byrd, C.; Lang, F.; et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity, 1995, 2(4), 341-351.
67. Grassme, H.; Jekle, A.; Riehle, A.; Schwarz, H.; Berger, J.; Sandhoff, K.; Kolesnick, R.; Gulbins, E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem., 2001, 276(23), 20589-20596.
68. Rosato, R.R.; Maggio, S.C.; Almenara, J.A.; Payne, S.G.; Atadja, P.; Spiegel, S.; Dent, P.; Grant, S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol., 2006, 69(1), 216-225.
69. Segui, B.; Legembre, P. Redistribution of CD95 into the lipid rafts to treat cancer cells? Recent Pat. Anticancer Drug Discov., 2010, 5(1), 22-28.
70. Castillo, S.S.; Levy, M.; Thaikoottathil, J.V.; Goldkorn, T. Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp. Cell. Res., 2007, 313(12), 2680-2686.
71. Grassme, H.; Bock, J.; Kun, J.; Gulbins, E. Clustering of CD40 ligand is required to form a functional contact with CD40. J. Biol. Chem., 2002, 277(33), 30289-30299.
72. Huang, Y.; Yang, J.; Shen, J.; Chen, F.F.; Yu, Y. Sphingolipids are involved in N-methyl-N'-nitro-N-nitrosoguanidine-induced epidermal growth factor receptor clustering. Biochem. Biophys. Res. Commun., 2005, 330(2), 430-438.
73. Lacour, S.; Hammann, A.; Grazide, S.; Lagadic-Gossmann, D.; Athias, A.; Sergent, O.; Laurent, G.; Gambert, P.; Solary, E.; Dimanche-Boitrel, M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res., 2004, 64(10), 3593-3598.
74. Heinrich, M.; Wickel, M.; Schneider-Brachert, W.; Sandberg, C.; Gahr, J.; Schwandner, R.; Weber, T.; Saftig, P.; Peters, C.; Brunner, J.; Kronke, M.; Schutze, S. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J., 1999, 18(19), 5252-5263.
75. Heinrich, M.; Neumeyer, J.; Jakob, M.; Hallas, C.; Tchikov, V.; Winoto-Morbach, S.; Wickel, M.; Schneider-Brachert, W.; Trauzold, A.; Hethke, A.; Schutze, S. Cathepsin D links TNFinduced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ., 2004, 11(5), 550-563.
76. Lansmann, S.; Schuette, C.G.; Bartelsen, O.; Hoernschemeyer, J.; Linke, T.; Weisgerber, J.; Sandhoff, K. Human acid sphingomyelinase. Eur. J. Biochem., 2003, 270(6), 1076-1088.
77. Qiu, H.; Edmunds, T.; Baker-Malcolm, J.; Karey, K.P.; Estes, S.; Schwarz, C.; Hughes, H.; Van Patten, S.M. Activation of human acid sphingomyelinase through modification or deletion of Cterminal cysteine. J. Biol. Chem., 2003, 278(35), 32744-32752.
78. Charruyer, A.; Grazide, S.; Bezombes, C.; Muller, S.; Laurent, G.; Jaffrezou, J.P. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J. Biol. Chem., 2005, 280(19), 19196-19204.
79. Dumitru, C.A.; Gulbins, E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene, 2006, 25(41), 5612-5625.
80. Zeidan, Y.H.; Jenkins, R.W.; Hannun, Y.A. Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell. Biol., 2008, 181(2), 335-350.
81. Edelmann, B.; Bertsch, U.; Tchikov, V.; Winoto-Morbach, S.; Perrotta, C.; Jakob, M.; Adam-Klages, S.; Kabelitz, D.; Schutze, S. Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J., 2011, 30(2), 379-394.
82. Nikolova-Karakashian, M.; Rozenova, K. Ceramide in stress response. Adv. Exp. Med. Biol., 2010, 688, 86-108.
83. Nikolova-Karakashian, M.; Karakashian, A.; Rutkute, K. Role of neutral sphingomyelinases in aging and inflammation. Subcell. Biochem., 2008, 49, 469-486.
84. Clarke, C.J.; Wu, B.X.; Hannun, Y.A. The neutral sphingomyelinase family: Identifying biochemical connections. Adv. Enzyme Regul., 2010.
85. Marchesini, N.; Osta, W.; Bielawski, J.; Luberto, C.; Obeid, L.M.; Hannun, Y.A. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J. Biol. Chem., 2004, 279(24), 25101-25111.
86. Levy, M.; Castillo, S.S.; Goldkorn, T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem. Biophys. Res. Commun., 2006, 344(3), 900-905.
87. Tani, M.; Hannun, Y.A. Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization. J. Biol. Chem., 2007, 282(13), 10047-10056.
88. Marchesini, N.; Luberto, C.; Hannun, Y.A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem., 2003, 278(16), 13775-13783.
89. Clarke, C.J.; Guthrie, J.M.; Hannun, Y.A. Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells. Mol. Pharmacol., 2008, 74(4), 1022-1032.
90. Tellier, E.; Negre-Salvayre, A.; Bocquet, B.; Itohara, S.; Hannun, Y.A.; Salvayre, R.; Auge, N. Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/ sphingolipid mitogenic pathway. Mol. Cell Biol., 2007, 27(8), 2997-3007.
91. Ito, H.; Murakami, M.; Furuhata, A.; Gao, S.; Yoshida, K.; Sobue, S.; Hagiwara, K.; Takagi, A.; Kojima, T.; Suzuki, M.; Banno, Y.; Tanaka, K.; Tamiya-Koizumi, K.; Kyogashima, M.; Nozawa, Y.; Murate, T. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim. Biophys. Acta, 2009, 1789(11-12), 681-690.
92. Clarke, C.J.; Truong, T.G.; Hannun, Y.A. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J. Biol. Chem., 2007, 282(2), 1384-1396.
93. De Palma, C.; Meacci, E.; Perrotta, C.; Bruni, P.; Clementi, E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol., 2006, 26(1), 99-105.
94. Adam-Klages, S.; Adam, D.; Wiegmann, K.; Struve, S.; Kolanus, W.; Schneider-Mergener, J.; Kronke, M. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell, 1996, 86(6), 937-947.
95. Philipp, S.; Puchert, M.; Adam-Klages, S.; Tchikov, V.; Winoto- Morbach, S.; Mathieu, S.; Deerberg, A.; Kolker, L.; Marchesini, N.; Kabelitz, D.; Hannun, Y.A.; Schutze, S.; Adam, D. The Polycomb group protein EED couples TNF receptor 1 to neutral sphingomyelinase. Proc. Natl. Acad. Sci. U S A, 2010, 107(3), 1112-1117.
96. Bourteele, S.; Hausser, A.; Doppler, H.; Horn-Muller, J.; Ropke, C.; Schwarzmann, G.; Pfizenmaier, K.; Muller, G. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J. Biol. Chem., 1998, 273(47), 31245-31251.
97. Dolgachev, V.; Farooqui, M.S.; Kulaeva, O.I.; Tainsky, M.A.; Nagy, B.; Hanada, K.; Separovic, D. De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells. J. Bio.l Chem., 2004, 279(22), 23238-23249.
98. Watanabe, M.; Kitano, T.; Kondo, T.; Yabu, T.; Taguchi, Y.; Tashima, M.; Umehara, H.; Domae, N.; Uchiyama, T.; Okazaki, T. Increase of nuclear ceramide through caspase-3-dependent regulation of the sphingomyelin cycle in Fas-induced apoptosis. Cancer Res., 2004, 64(3), 1000-1007.
99. Lafont, E.; Milhas, D.; Carpentier, S.; Garcia, V.; Jin, Z.X.; Umehara, H.; Okazaki, T.; Schulze-Osthoff, K.; Levade, T.; Benoist, H.; Segui, B. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death Differ., 2010, 17(4), 642-654.
100. Chalfant, C.E.; Ogretmen, B.; Galadari, S.; Kroesen, B.J.; Pettus, B.J.; Hannun, Y.A. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. J. Biol. Chem., 2001, 276(48), 44848-44855.
101. Marchesini, N.; Jones, J.A.; Hannun, Y.A. Confluence induced threonine41/serine45 phospho-beta-catenin dephosphorylation via ceramide-mediated activation of PP1cgamma. Biochim. Biophys. Acta, 2007, 1771(12), 1418-1428.
102. Kim, S.W.; Kim, H.J.; Chun, Y.J.; Kim, M.Y. Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J. Toxicol. Environ. Health A., 2010, 73(21-22), 1465-1476.
103. Zhou, H.; Summers, S.A.; Birnbaum, M.J.; Pittman, R.N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol.Chem., 1998, 273(26), 16568-16575.
104. Chalfant, C.E.; Kishikawa, K.; Mumby, M.C.; Kamibayashi, C.; Bielawska, A.; Hannun, Y.A. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J. Biol. Chem., 1999, 274(29), 20313-20317.
105. Mukhopadhyay, A.; Saddoughi, S.A.; Song, P.; Sultan, I.; Ponnusamy, S.; Senkal, C.E.; Snook, C.F.; Arnold, H.K.; Sears, R.C.; Hannun, Y.A.; Ogretmen, B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J., 2009, 23(3), 751-763.
106. Lee, J.Y.; Hannun, Y.A.; Obeid, L.M. Ceramide inactivates cellular protein kinase Calpha. J. Biol. Chem., 1996, 271(22), 13169-13174.
107. Muller, G.; Ayoub, M.; Storz, P.; Rennecke, J.; Fabbro, D.; Pfizenmaier, K. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. E.M.B.O. J., 1995, 14(9), 1961-1969.
108. Bourbon, N.A.; Sandirasegarane, L.; Kester, M. Ceramideinduced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J. Biol. Chem., 2002, 277(5), 3286-3292.
109. Zhang, Y.; Yao, B.; Delikat, S.; Bayoumy, S.; Lin, X.H.; Basu, S.; McGinley, M.; Chan-Hui, P.Y.; Lichenstein, H.; Kolesnick, R. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell, 1997, 89(1), 63-72.
110. Lee, M.J.; Van Brocklyn, J.R.; Thangada, S.; Liu, C.H.; Hand, A.R.; Menzeleev, R.; Spiegel, S.; Hla, T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science, 1998, 279(5356), 1552-1555.
111. Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol., 2003, 4(5), 397-407.
112. Boujaoude, L.C.; Bradshaw-Wilder, C.; Mao, C.; Cohn, J.; Ogretmen, B.; Hannun, Y.A.; Obeid, L.M. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J. Biol. Chem., 2001, 276(38), 35258-35264.
113. Mitra, P.; Oskeritzian, C.A.; Payne, S.G.; Beaven, M.A.; Milstien, S.; Spiegel, S. Role of ABCC1 in export of sphingosine-1- phosphate from mast cells. Proc. Natl. Acad. Sci. U S A, 2006, 103(44), 16394-16399.
114. Doll, F.; Pfeilschifter, J.; Huwiler, A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim. Biophys. Acta, 2005, 1738(1-3), 72-81.
115. Sukocheva, O.A.; Wang, L.; Albanese, N.; Pitson, S.M.; Vadas, M.A.; Xia, P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol. Endocrinol., 2003, 17(10), 2002-2012.
116. Nakade, Y.; Banno, YKTK.; Hagiwara, K.; Sobue, S.; Koda, M.; Suzuki, M.; Kojima, T.; Takagi, A.; Asano, H.; Nozawa, Y.; Murate, T. Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim. Biophys. Acta, 2003, 1635(2-3), 104-116.
117. Huwiler, A.; Doll, F.; Ren, S.; Klawitter, S.; Greening, A.; Romer, I.; Bubnova, S.; Reinsberg, L.; Pfeilschifter, J. Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. Biochim. Biophys. Acta, 2006, 1761(3), 367-376.
118. Klawitter, S.; Hofmann, L.P.; Pfeilschifter, J.; Huwiler, A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br. J. Pharmacol., 2007, 150(3), 271-280.
119. Pitson, S.M.; Moretti, P.A.; Zebol, J.R.; Lynn, H.E.; Xia, P.; Vadas, M.A.; Wattenberg, B.W. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. E.M.B.O. J., 2003, 22(20), 5491-5500.
120. Jarman, K.E.; Moretti, P.A.; Zebol, J.R.; Pitson, S.M. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J. Biol. Chem., 2010, 285(1), 483-492.
121. Alvarez, S.E.; Harikumar, K.B.; Hait, N.C.; Allegood, J.; Strub, G.M.; Kim, E.Y.; Maceyka, M.; Jiang, H.; Luo, C.; Kordula, T.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 2010, 465(7301), 1084-1088.
122. Ghosh, T.K.; Bian, J.; Gill, D.L. Sphingosine 1-phosphate generated in the endoplasmic reticulum membrane activates release of stored calcium. J. Biol. Chem., 1994, 269(36), 22628-22635.
123. Thompson, C.R.; Iyer, S.S.; Melrose, N.; VanOosten, R.; Johnson, K.; Pitson, S.M.; Obeid, L.M.; Kusner, D.J. Sphingosine kinase 1 (SK1) is recruited to nascent phagosomes in human macrophages: inhibition of SK1 translocation by Mycobacterium tuberculosis. J. Immunol., 2005, 174(6), 3551-3561.
124. Venkataraman, K.; Thangada, S.; Michaud, J.; Oo, M.L.; Ai, Y.; Lee, Y.M.; Wu, M.; Parikh, N.S.; Khan, F.; Proia, R.L.; Hla, T. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem. J., 2006, 397(3), 461-471.
125. Hammad, S.M.; Taha, T.A.; Nareika, A.; Johnson, K.R.; Lopes-Virella, M.F.; Obeid, L.M. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat., 2006, 79(1-2), 126-140.
126. Hait, N.C.; Allegood, J.; Maceyka, M.; Strub, G.M.; Harikumar, K.B.; Singh, S.K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325(5945), 1254-1257.
127. Igarashi, N.; Okada, T.; Hayashi, S.; Fujita, T.; Jahangeer, S.; Nakamura, S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem., 2003, 278(47), 46832-46839.
128. Liu, H.; Toman, R.E.; Goparaju, S.K.; Maceyka, M.; Nava, V.E.; Sankala, H.; Payne, S.G.; Bektas, M.; Ishii, I.; Chun, J.; Milstien, S.; Spiegel, S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem., 2003, 278(41), 40330-40336.
129. Mizugishi, K.; Yamashita, T.; Olivera, A.; Miller, G.F.; Spiegel, S.; Proia, R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol., 2005, 25(24), 11113-11121.
130. Xia, P.; Gamble, J.R.; Wang, L.; Pitson, S.M.; Moretti, P.A.; Wattenberg, B.W.; D'Andrea, R.J.; Vadas, M.A. An oncogenic role of sphingosine kinase. Curr. Biol., 2000, 10(23), 1527-1530.
131. Kapitonov, D.; Allegood, J.C.; Mitchell, C.; Hait, N.C.; Almenara, J.A.; Adams, J.K.; Zipkin, R.E.; Dent, P.; Kordula, T.; Milstien, S.; Spiegel, S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res., 2009, 69(17), 6915-6923.
132. Kawamori, T.; Osta, W.; Johnson, K.R.; Pettus, B.J.; Bielawski, J.; Tanaka, T.; Wargovich, M.J.; Reddy, B.S.; Hannun, Y.A.; Obeid, L.M.; Zhou, D. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J., 2006, 20(2), 386-388.
133. Kawamori, T.; Kaneshiro, T.; Okumura, M.; Maalouf, S.; Uflacker, A.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J., 2009, 23(2), 405-414.
134. Facchinetti, M.M.; Gandini, N.A.; Fermento, M.E.; Sterin-Speziale, N.B.; Ji, Y.; Patel, V.; Gutkind, J.S.; Rivadulla, M.G.; Curino, A.C. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs, 2010, 192(5), 314-324.
135. Shirai, K.; Kaneshiro, T.; Wada, M.; Furuya, H.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M.; Ogretmen, B.; Kawamori, T. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev. Res. (Phila.), 2011, 4(3), 454-462.
136. French, K.J.; Schrecengost, R.S.; Lee, B.D.; Zhuang, Y.; Smith, S.N.; Eberly, J.L.; Yun, J.K.; Smith, C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63(18), 5962-5969.
137. Johnson, K.R.; Johnson, K.Y.; Crellin, H.G.; Ogretmen, B.; Boylan, A.M.; Harley, R.A.; Obeid, L.M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem., 2005, 53(9), 1159-1166.
138. Sobue, S.; Iwasaki, T.; Sugisaki, C.; Nagata, K.; Kikuchi, R.; Murakami, M.; Takagi, A.; Kojima, T.; Banno, Y.; Akao, Y.; Nozawa, Y.; Kannagi, R.; Suzuki, M.; Abe, A.; Naoe, T.; Murate, T. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia, 2006, 20(11), 2042-2046.
139. Shirai, K.; Kaneshiro, T.; Wada, M.; Furuya, H.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M.; Ogretmen, B.; Kawamori, T. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev. Res. (Phila.), 2011, 4(3), 454-462.
140. Doll, F.; Pfeilschifter, J.; Huwiler, A. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocr. Relat. Cancer, 2007, 14(2), 325-335.
141. Sarkar, S.; Maceyka, M.; Hait, N.C.; Paugh, S.W.; Sankala, H.; Milstien, S.; Spiegel, S. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. F.E.B.S. Lett., 2005, 579(24), 5313-5317.
142. Liu, F.; Verin, A.D.; Wang, P.; Day, R.; Wersto, R.P.; Chrest, F.J.; English, D.K.; Garcia, J.G. Differential regulation of sphingosine- 1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am. J. Respir. Cell. Mol. Biol., 2001, 24(6), 711-719.
143. Annabi, B.; Thibeault, S.; Lee, Y.T.; Bousquet-Gagnon, N.; Eliopoulos, N.; Barrette, S.; Galipeau, J.; Beliveau, R. Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp. Hematol., 2003, 31(7), 640-649.
144. Lee, M.J.; Thangada, S.; Claffey, K.P.; Ancellin, N.; Liu, C.H.; Kluk, M.; Volpi, M.; Sha'afi, R.I.; Hla, T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell, 1999, 99(3), 301-312.
145. Argraves, K.M.; Wilkerson, B.A.; Argraves, W.S.; Fleming, P.A.; Obeid, L.M.; Drake, C.J. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J. Biol. Chem., 2004, 279(48), 50580-50590.
146. Limaye, V.; Li, X.; Hahn, C.; Xia, P.; Berndt, M.C.; Vadas, M.A.; Gamble, J.R. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood, 2005, 105(8), 3169-3177.
147. Visentin, B.; Vekich, J.A.; Sibbald, B.J.; Cavalli, A.L.; Moreno, K.M.; Matteo, R.G.; Garland, W.A.; Lu, Y.; Yu, S.; Hall, H.S.; Kundra, V.; Mills, G.B.; Sabbadini, R.A. Validation of an antisphingosine- 1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9(3), 225-238.
148. Futerman, A.H.; Hannun, Y.A. The complex life of simple sphingolipids. E.M.B.O. Rep., 2004, 5(8), 777-782.
149. Hanada, K.; Kumagai, K.; Yasuda, S.; Miura, Y.; Kawano, M.; Fukasawa, M.; Nishijima, M. Molecular machinery for non-vesicular trafficking of ceramide. Nature, 2003, 426(6968), 803-809.
150. Simon, C.G., Jr.; Holloway, P.W.; Gear, A.R. Exchange of C(16)- ceramide between phospholipid vesicles. Biochemistry, 1999, 38(44), 14676-14682.
151. Bai, J.; Pagano, R.E. Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles. Biochemistry, 1997, 36(29), 8840-8848.
152. van Meer, G.; Holthuis, J.C. Sphingolipid transport in eukaryotic cells. Biochim. Biophys. Acta, 2000, 1486(1), 145-170.
153. Stiban, J.; Tidhar, R.; Futerman, A.H. Ceramide synthases: roles in cell physiology and signaling. Adv. Exp. Med. Biol., 2010, 688, 60-71.
154. Ternes, P.; Franke, S.; Zahringer, U.; Sperling, P.; Heinz, E. Identification and characterization of a sphingolipid delta 4- desaturase family. J. Biol. Chem., 2002, 277(28), 25512-25518.
155. Huitema, K.; van den Dikkenberg, J.; Brouwers, J.F.; Holthuis, J.C. Identification of a family of animal sphingomyelin synthases. E.M.B.O. J., 2004, 23(1), 33-44.
156. Villani, M.; Subathra, M.; Im, Y.B.; Choi, Y.; Signorelli, P.; Del Poeta, M.; Luberto, C. Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. Biochem. J., 2008, 414(1), 31-41.
157. Senkal, C.E.; Ponnusamy, S.; Bielawski, J.; Hannun, Y.A.; Ogretmen, B. Antiapoptotic roles of ceramide-synthase-6- generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J., 2010, 24(1), 296-308.
158. Kroesen, B.J.; Jacobs, S.; Pettus, B.J.; Sietsma, H.; Kok, J.W.; Hannun, Y.A.; de Leij, L.F. BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J. Biol. Chem., 2003, 278(17), 14723-14731.
159. White-Gilbertson, S.; Mullen, T.; Senkal, C.; Lu, P.; Ogretmen, B.; Obeid, L.; Voelkel-Johnson, C. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene, 2009, 28(8), 1132-1141.
160. Venkataraman, K.; Riebeling, C.; Bodennec, J.; Riezman, H.; Allegood, J.C.; Sullards, M.C.; Merrill, A.H., Jr.; Futerman, A.H. Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro) ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J. Biol. Chem., 2002, 277(38), 35642-35649.
161. Ullman, M.D.; Radin, N.S. The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. J. Biol. Chem., 1974, 249(5), 1506-1512.
162. Griner, E.M.; Kazanietz, M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer, 2007, 7(4), 281-294.
163. Yang, C.; Kazanietz, M.G. Chimaerins: GAPs that bridge diacylglycerol signalling and the small G-protein Rac. Biochem. J., 2007, 403(1), 1-12.
164. Carrasco, S.; Merida, I. Diacylglycerol, when simplicity becomes complex. Trends Biochem. Sci., 2007, 32(1), 27-36.
165. Colon-Gonzalez, F.; Kazanietz, M.G. C1 domains exposed: from diacylglycerol binding to protein-protein interactions. Biochim. Biophys. Acta, 2006, 1761(8), 827-837.
166. Luberto, C.; Hannun, Y.A. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J. Biol. Chem., 1998, 273(23), 14550-14559.
167. Miro-Obradors, M.J.; Osada, J.; Aylagas, H.; Sanchez-Vegazo, I.; Palacios-Alaiz, E. Microsomal sphingomyelin accumulation in thioacetamide-injured regenerating rat liver: involvement of sphingomyelin synthase activity. Carcinogenesis, 1993, 14(5), 941-946.
168. Riboni, L.; Viani, P.; Bassi, R.; Giussani, P.; Tettamanti, G. Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis. J. Biol. Chem., 2001, 276(16), 12797-12804.
169. Yano, M.; Watanabe, K.; Yamamoto, T.; Ikeda, K.; Senokuchi, T.; Lu, M.; Kadomatsu, T.; Tsukano, H.; Ikawa, M.; Okabe, M.; Yamaoka, S.; Okazaki, T.; Umehara, H.; Gotoh, T.; Song, W.J.; Node, K.; Taguchi, R.; Yamagata, K.; Oike, Y. Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J. Biol. Chem., 2011, 286(5), 3992-4002.
170. Vardiman, J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem. Biol. Interact., 2009, 184(1-2), 16-20.
171. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol., 1976, 33(4), 451-458.
172. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. A variant form of hypergranular promyelocytic leukaemia (M3). Br. J. Haematol., 1980, 44(1), 169-170.
173. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French- American-British Cooperative Group. Ann. Intern. Med., 1985, 103(3), 460-462.
174. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br. J. Haematol., 1991, 78(3), 325-329.
175. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French- American-British Cooperative Group. Ann. Intern. Med., 1985, 103(4), 620-625.
176. Harris, N.L.; Jaffe, E.S.; Diebold, J.; Flandrin, G.; Muller- Hermelink, H.K.; Vardiman, J.; Lister, T.A.; Bloomfield, C.D. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol. J., 2000, 1(1), 53-66.
177. Jabbour, E.J.; Faderl, S.; Kantarjian, H.M. Adult acute lymphoblastic leukemia. Mayo Clin. Proc., 2005, 80(11), 1517-1527.
178. rd ed.; Lippincott Williams and Wilkins: Jefferson City, 2010.
179. Cairns, J. Mutation selection and the natural history of cancer. Nature, 1975, 255(5505), 197-200.
180. Morrison, S.J.; Kimble, J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature, 2006, 441(7097), 1068-1074.
181. Watt, F.M.; Hogan, B.L. Out of Eden: stem cells and their niches. Science, 2000, 287(5457), 1427-1430.
182. Papayannopoulou, T.; Lemischka, I. In: The Molecular Basis of Blood Disease; Stamatoyannopoulos, G., Ed.; 3 ed.; W.B. Saunders Company: Philadelphia, 2001; pp. 1-24.
183. Morrison, S.J.; Weissman, I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity, 1994, 1(8), 661-673.
184. Sato, T.; Laver, J.H.; Ogawa, M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood, 1999, 94(8), 2548-2554.
185. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
186. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367(6464), 645-648.
187. Dick, J.E.; Lapidot, T. Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol., 2005, 82(5), 389-396.
188. Huntly, B.J.; Gilliland, D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer, 2005, 5(4), 311-321.
189. Collins, S.J.; Gallo, R.C.; Gallagher, R.E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature, 1977, 270(5635), 347-349.
190. Kim, M.Y.; Linardic, C.; Obeid, L.; Hannun, Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J. Biol. Chem., 1991, 266(1), 484-489.
191. Dbaibo, G.S.; Pushkareva, M.Y.; Jayadev, S.; Schwarz, J.K.; Horowitz, J.M.; Obeid, L.M.; Hannun, Y.A. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc. Natl. Acad. Sci. U S A, 1995, 92(5), 1347-1351.
192. Wolff, R.A.; Dobrowsky, R.T.; Bielawska, A.; Obeid, L.M.; Hannun, Y.A. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem., 1994, 269(30), 19605-19609.
193. Mathias, S.; Younes, A.; Kan, C.C.; Orlow, I.; Joseph, C.; Kolesnick, R.N. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science, 1993, 259(5094), 519-522.
194. Furuya, S.; Mitoma, J.; Makino, A.; Hirabayashi, Y. Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells. J. Neurochem., 1998, 71(1), 366-377.
195. Ragg, S.J.; Kaga, S.; Berg, K.A.; Ochi, A. The mitogen-activated protein kinase pathway inhibits ceramide-induced terminal differentiation of a human monoblastic leukemia cell line, U937. J. Immunol., 1998, 161(3), 1390-1398.
196. Hannun, Y.A.; Luberto, C. Ceramide in the eukaryotic stress response. Trends Cell. Biol., 2000, 10(2), 73-80.
197. Hannun, Y.A.; Obeid, L.M. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem., 2002, 277(29), 25847-25850.
198. Jaffrezou, J.P.; Levade, T.; Bettaieb, A.; Andrieu, N.; Bezombes, C.; Maestre, N.; Vermeersch, S.; Rousse, A.; Laurent, G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. E.M.B.O. J., 1996, 15(10), 2417-2424.
199. Sonneveld, P. Multidrug resistance in haematological malignancies. J. Intern. Med., 2000, 247(5), 521-534.
200. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20(1), 95-102.
201. Senchenkov, A.; Han, T.Y.; Wang, H.; Frankel, A.E.; Kottke, T.J.; Kaufmann, S.H.; Cabot, M.C. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GMCSF), a truncated diphtheria toxin fused to human GM-CSF. Blood, 2001, 98(6), 1927-1934.
202. Cakir, Z.; Saydam, G.; Sahin, F.; Baran, Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J. Cancer Res. Clin. Oncol., 2011.
203. Advani, A.; Lazarus, H. Adult Acute Lymphocytic Leukemia: Biology and Treatment, 1st ed.; Springer Verlag, 2010.
204. Biswal, S.S.; Datta, K.; Acquaah-Mensah, G.K.; Kehrer, J.P. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology, 2000, 154(1-3), 45-53.
205. Herr, I.; Wilhelm, D.; Bohler, T.; Angel, P.; Debatin, K.M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. E.M.B.O. J., 1997, 16(20), 6200-6208.
206. Zhang, J.; Alter, N.; Reed, J.C.; Borner, C.; Obeid, L.M.; Hannun, Y.A. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acad. Sci. U S A, 1996, 93(11), 5325-5328.
207. Olshefski, R.S.; Ladisch, S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int. J. Cancer, 2001, 93(1), 131-138.
208. Gruber, C.; Henkel, M.; Budach, W.; Belka, C.; Jendrossek, V. Involvement of tyrosine kinase p56/Lck in apoptosis induction by anticancer drugs. Biochem. Pharmacol., 2004, 67(10), 1859-1872.
209. Sillence, D.J.; Allan, D. Evidence against an early signalling role for ceramide in Fas-mediated apoptosis. Biochem. J., 1997, 324 (Pt 1), 29-32.
210. Watts, J.D.; Gu, M.; Polverino, A.J.; Patterson, S.D.; Aebersold, R. Fas-induced apoptosis of T cells occurs independently of ceramide generation. Proc. Natl Acad. Sci. U S A, 1997, 94(14), 7292-7296.
211. Brenner, B.; Ferlinz, K.; Grassme, H.; Weller, M.; Koppenhoefer, U.; Dichgans, J.; Sandhoff, K.; Lang, F.; Gulbins, E. Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. Cell Death Differ., 1998, 5(1), 29-37.
212. Cock, J.G.; Tepper, A.D.; de Vries, E.; van Blitterswijk, W.J.; Borst, J. CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase. J. Biol. Chem., 1998, 273(13), 7560-7565.
213. Cuvillier, O.; Rosenthal, D.S.; Smulson, M.E.; Spiegel, S. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J. Biol. Chem., 1998, 273(5), 2910-2916.
214. Hsu, S.C.; Wu, C.C.; Luh, T.Y.; Chou, C.K.; Han, S.H.; Lai, M.Z. Apoptotic signal of Fas is not mediated by ceramide. Blood, 1998, 91(8), 2658-2663.
215. Rodriguez-Lafrasse, C.; Alphonse, G.; Broquet, P.; Aloy, M.T.; Louisot, P.; Rousson, R. Temporal relationships between ceramide production, caspase activation and mitochondrial dysfunction in cell lines with varying sensitivity to anti-Fas-induced apoptosis. Biochem. J., 2001, 357(Pt 2), 407-416.
216. Caricchio, R.; D'Adamio, L.; Cohen, P.L. Fas, ceramide and serum withdrawal induce apoptosis via a common pathway in a type II Jurkat cell line. Cell Death Differ., 2002, 9(5), 574-580.
217. Hetz, C.A.; Hunn, M.; Rojas, P.; Torres, V.; Leyton, L.; Quest, A.F. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. J. Cell Sci., 2002, 115(Pt 23), 4671-4683.
218. Grassme, H.; Cremesti, A.; Kolesnick, R.; Gulbins, E. Ceramidemediated clustering is required for CD95-DISC formation. Oncogene, 2003, 22(35), 5457-5470.
219. Rotolo, J.A.; Zhang, J.; Donepudi, M.; Lee, H.; Fuks, Z.; Kolesnick, R. Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J. Biol. Chem., 2005, 280(28), 26425-26434.
220. Chaigne-Delalande, B.; Moreau, J.F.; Legembre, P. Rewinding the DISC. Arch. Immunol. Ther. Exp. (Warsz), 2008, 56(1), 9-14.
221. Cremesti, A.; Paris, F.; Grassme, H.; Holler, N.; Tschopp, J.; Fuks, Z.; Gulbins, E.; Kolesnick, R. Ceramide enables fas to cap and kill. J. Biol. Chem., 2001, 276(26), 23954-23961.
222. Jin, Z.X.; Huang, C.R.; Dong, L.; Goda, S.; Kawanami, T.; Sawaki, T.; Sakai, T.; Tong, X.P.; Masaki, Y.; Fukushima, T.; Tanaka, M.; Mimori, T.; Tojo, H.; Bloom, E.T.; Okazaki, T.; Umehara, H. Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int. Immunol., 2008, 20(11), 1427-1437.
223. Miyaji, M.; Jin, Z.X.; Yamaoka, S.; Amakawa, R.; Fukuhara, S.; Sato, S.B.; Kobayashi, T.; Domae, N.; Mimori, T.; Bloom, E.T.; Okazaki, T.; Umehara, H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med., 2005, 202(2), 249-259.
224. Yamaoka, S.; Miyaji, M.; Kitano, T.; Umehara, H.; Okazaki, T. Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J. Biol. Chem., 2004, 279(18), 18688-18693.
225. Chatterjee, M.; Wu, S. Cell line dependent involvement of ceramide in ultraviolet light-induced apoptosis. Mol. Cell. Biochem., 2001, 219(1-2), 21-27.
226. Matsko, C.M.; Hunter, O.C.; Rabinowich, H.; Lotze, M.T.; Amoscato, A.A. Mitochondrial lipid alterations during Fas- and radiation-induced apoptosis. Biochem. Biophys. Res. Commun., 2001, 287(5), 1112-1120.
227. Alphonse, G.; Aloy, M.T.; Broquet, P.; Gerard, J.P.; Louisot, P.; Rousson, R.; Rodriguez-Lafrasse, C. Ceramide induces activation of the mitochondrial/caspases pathway in Jurkat and SCC61 cells sensitive to gamma-radiation but activation of this sequence is defective in radioresistant SQ20B cells. Int. J. Radiat. Biol., 2002, 78(9), 821-835.
228. Rodriguez-Lafrasse, C.; Alphonse, G.; Aloy, M.T.; Ardail, D.; Gerard, J.P.; Louisot, P.; Rousson, R. Increasing endogenous ceramide using inhibitors of sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial injury and apoptotic cell killing. Int. J. Cancer, 2002, 101(6), 589-598.
229. Herrera, B.; Carracedo, A.; Diez-Zaera, M.; Gomez del Pulgar, T.; Guzman, M.; Velasco, G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp. Cell. Res., 2006, 312(11), 2121-2131.
230. Ion, G.; Fajka-Boja, R.; Kovacs, F.; Szebeni, G.; Gombos, I.; Czibula, A.; Matko, J.; Monostori, E. Acid sphingomyelinase mediated release of ceramide is essential to trigger the mitochondrial pathway of apoptosis by galectin-1. Cell. Signal., 2006, 18(11), 1887-1896.
231. Ardail, D.; Maalouf, M.; Boivin, A.; Chapet, O.; Bodennec, J.; Rousson, R.; Rodriguez-Lafrasse, C. Diversity and complexity of ceramide generation after exposure of jurkat leukemia cells to irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2009, 73(4), 1211-1218.
232. Granot, T.; Milhas, D.; Carpentier, S.; Dagan, A.; Segui, B.; Gatt, S.; Levade, T. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia, 2006, 20(3), 392-399.
233. Villena, J.; Henriquez, M.; Torres, V.; Moraga, F.; Diaz-Elizondo, J.; Arredondo, C.; Chiong, M.; Olea-Azar, C.; Stutzin, A.; Lavandero, S.; Quest, A.F. Ceramide-induced formation of ROS and ATP depletion trigger necrosis in lymphoid cells. Free Radic. Biol. Med., 2008, 44(6), 1146-1160.
234. Furlong, S.J.; Ridgway, N.D.; Hoskin, D.W. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int. J. Oncol., 2008, 32(3), 537-544.
235. Paugh, S.W.; Paugh, B.S.; Rahmani, M.; Kapitonov, D.; Almenara, J.A.; Kordula, T.; Milstien, S.; Adams, J.K.; Zipkin, R.E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112(4), 1382-1391.
236. Separovic, D.; Hanada, K.; Maitah, M.Y.; Nagy, B.; Hang, I.; Tainsky, M.A.; Kraniak, J.M.; Bielawski, J. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis postphotodamage. Biochem. Biophys. Res. Commun., 2007, 358(1), 196-202.
237. Separovic, D.; Semaan, L.; Tarca, A.L.; Awad Maitah, M.Y.; Hanada, K.; Bielawski, J.; Villani, M.; Luberto, C. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. Exp. Cell. Res., 2008, 314(8), 1860-1868.
238. Lin, C.F.; Chen, C.L.; Chang, W.T.; Jan, M.S.; Hsu, L.J.; Wu, R.H.; Tang, M.J.; Chang, W.C.; Lin, Y.S. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis. J. Biol. Chem., 2004, 279(39), 40755-40761.
239. Chen, C.L.; Lin, C.F.; Chang, W.T.; Huang, W.C.; Teng, C.F.; Lin, Y.S. Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood, 2008, 111(8), 4365-4374.
240. Jayadev, S.; Liu, B.; Bielawska, A.E.; Lee, J.Y.; Nazaire, F.; Pushkareva, M.; Obeid, L.M.; Hannun, Y.A. Role for ceramide in cell cycle arrest. J. Biol. Chem., 1995, 270(5), 2047-2052.
241. Lee, J.Y.; Bielawska, A.E.; Obeid, L.M. Regulation of cyclindependent kinase 2 activity by ceramide. Exp. Cell. Res., 2000, 261(2), 303-311.
242. Laethem, R.M.; Hannun, Y.A.; Jayadev, S.; Sexton, C.J.; Strum, J.C.; Sundseth, R.; Smith, G.K. Increases in neutral, Mg2+- dependent and acidic, Mg2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843. Blood, 1998, 91(11), 4350-4360.
243. Dbaibo, G.S.; Pushkareva, M.Y.; Rachid, R.A.; Alter, N.; Smyth, M.J.; Obeid, L.M.; Hannun, Y.A. p53-dependent ceramide response to genotoxic stress. J. Clin. Invest., 1998, 102(2), 329-339.
244. Panjarian, S.; Kozhaya, L.; Arayssi, S.; Yehia, M.; Bielawski, J.; Bielawska, A.; Usta, J.; Hannun, Y.A.; Obeid, L.M.; Dbaibo, G.S. De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation. Prostaglandins Other Lipid Mediat., 2008, 86(1-4), 41-48.
245. Kim, W.J.; Okimoto, R.A.; Purton, L.E.; Goodwin, M.; Haserlat, S.M.; Dayyani, F.; Sweetser, D.A.; McClatchey, A.I.; Bernard, O.A.; Look, A.T.; Bell, D.W.; Scadden, D.T.; Haber, D.A. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood, 2008, 111(9), 4716-4722.
246. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S.F.; Kaiser, J.; Shanmugavelandy, S.S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K.T.; Jarbadan, N.R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T.J.; Kester, M.; Loughran, T.P., Jr. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116(20), 4192-4201.
247. Shah, M.V.; Zhang, R.; Irby, R.; Kothapalli, R.; Liu, X.; Arrington, T.; Frank, B.; Lee, N.H.; Loughran, T.P., Jr. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood, 2008, 112(3), 770-781.
248. Kabarowski, J.H.; Witte, O.N. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells, 2000, 18(6), 399-408.
249. Rowley, J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973, 243(5405), 290-293.
250. Deininger, M.W.; Goldman, J.M.; Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood, 2000, 96(10), 3343-3356.
251. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer, 2005, 5(3), 172-183.
252. Wong, S.; Witte, O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol., 2004, 22, 247-306.
253. Karbasian Esfahani, M.; Morris, E.L.; Dutcher, J.P.; Wiernik, P.H. Blastic phase of chronic myelogenous leukemia. Curr. Treat. Options Oncol., 2006, 7(3), 189-199.
254. Quintas-Cardama, A.; Cortes, J. Molecular biology of bcrabl1- positive chronic myeloid leukemia. Blood, 2009, 113(8), 1619-1630.
255. Marley, S.B.; Gordon, M.Y. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin. Sci. (Lond), 2005, 109(1), 13-25.
256. Sessions, J. Chronic myeloid leukemia in 2007. Am. J. Health Syst. Pharm., 2007, 64(24 Suppl 15), S4-S9.
257. Pendergast, A.M.; Quilliam, L.A.; Cripe, L.D.; Bassing, C.H.; Dai, Z.; Li, N.; Batzer, A.; Rabun, K.M.; Der, C.J.; Schlessinger, J.; et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 1993, 75(1), 175-185.
258. Skorski, T.; Kanakaraj, P.; Nieborowska-Skorska, M.; Ratajczak, M.Z.; Wen, S.C.; Zon, G.; Gewirtz, A.M.; Perussia, B.; Calabretta, B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 1995, 86(2), 726-736.
259. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B.W.; Liu, S.; Mao, H.; Chang, J.S.; Galietta, A.; Uttam, A.; Roy, D.C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M.A.; Bloomfield, C.D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8(5), 355-368.
260. Perrotti, D.; Neviani, P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br. J. Cancer, 2006, 95(7), 775-781.
261. Perrotti, D.; Neviani, P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev., 2008, 27(2), 159-168.
262. Lydon, N.B.; Druker, B.J. Lessons learned from the development of imatinib. Leuk. Res., 2004, 28 Suppl 1, S29-S38.
263. Marin, D.; Marktel, S.; Bua, M.; Armstrong, L.; Goldman, J.M.; Apperley, J.F.; Olavarria, E. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica, 2002, 87(9), 979-988.
264. Ross, J.S.; Schenkein, D.P.; Pietrusko, R.; Rolfe, M.; Linette, G.P.; Stec, J.; Stagliano, N.E.; Ginsburg, G.S.; Symmans, W.F.; Pusztai, L.; Hortobagyi, G.N. Targeted therapies for cancer 2004. Am. J. Clin. Pathol., 2004, 122(4), 598-609.
265. Spellberg, B.J.; Collins, M.; Avanesian, V.; Gomez, M.; Edwards, J.E., Jr.; Cogle, C.; Applebaum, D.; Fu, Y.; Ibrahim, A.S. Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J. Leukoc. Biol., 2007, 81(3), 632-641.
266. Apperley, J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol., 2007, 8(11), 1018-1029.
267. Kantarjian, H.M.; Talpaz, M.; Kontoyiannis, D.; Gutterman, J.; Keating, M.J.; Estey, E.H.; O'Brien, S.; Rios, M.B.; Beran, M.; Deisseroth, A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol., 1992, 10(3), 398-405.
268. Kantarjian, H.M.; Walters, R.S.; Keating, M.J.; Talpaz, M.; Andersson, B.; Beran, M.; McCredie, K.B.; Freireich, E.J. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer, 1988, 62(4), 672-676.
269. Morris, M.J. Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. Nat. Clin. Pract. Oncol., 2006, 3(10), 536-537.
270. Koller, C.A.; Miller, D.M. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N. Engl. J. Med., 1986, 315(23), 1433-1438.
271. Axdorph, U.; Stenke, L.; Grimfors, G.; Carneskog, J.; Hansen, J.; Linder, O.; Ljungman, P.; Lofvenberg, E.; Malm, C.; Simonsson, B.; Turesson, I.; Vilen, L.; Uden, A.M.; Bjorkholm, M. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br. J. Haematol., 2002, 118(4), 1048-1054.
272. Amarante-Mendes, G.P.; Naekyung Kim, C.; Liu, L.; Huang, Y.; Perkins, C.L.; Green, D.R.; Bhalla, K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 1998, 91(5), 1700-1705.
273. Maguer-Satta, V. CML and apoptosis: the ceramide pathway. Hematol. Cell. Ther., 1998, 40(5), 233-236.
274. Nica, A.F.; Tsao, C.C.; Watt, J.C.; Jiffar, T.; Kurinna, S.; Jurasz, P.; Konopleva, M.; Andreeff, M.; Radomski, M.W.; Ruvolo, P.P. Ceramide promotes apoptosis in chronic myelogenous leukemiaderived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle, 2008, 7(21), 3362-3370.
275. Maguer-Satta, V.; Burl, S.; Liu, L.; Damen, J.; Chahine, H.; Krystal, G.; Eaves, A.; Eaves, C. BCR-ABL accelerates C2- ceramide-induced apoptosis. Oncogene, 1998, 16(2), 237-248.
276. Li, Q.F.; Huang, W.R.; Duan, H.F.; Wang, H.; Wu, C.T.; Wang, L.S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene, 2007, 26(57), 7904-7908.
277. Wang, F.X.; Dong, Z.R.; Liu, Z.L.; Pan, L.; Luo, J.M.; Zhang, X.J.; Hao, H.L.; Li, X.L.; Yang, J.C.; Jiang, L.L. mitochondrial ceramidase overexpression up-regulates Bcl-2 protein level in K562 cells, probably through its metabolite sphingosine-1- phosphate. Zhongguo. Shi. Yan. Xue. Ye. Xue. Za. Zhi., 2004, 12(5), 577-583.
278. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1- phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282(15), 10922-10934.
279. Bonhoure, E.; Lauret, A.; Barnes, D.; J. Martin, C.; Malavaud, B.; Kohama, T.; Melo, J.V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22(5), 971-979.
280. Bonhoure, E.; Lauret, A.; Barnes, D.; Jmartin, C. Malavaud B. Kohama; T. Melo; J. V. Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22(5), 971-979.
281. Ricci, C.; Onida, F.; Servida, F.; Radaelli, F.; Saporiti, G.; Todoerti, K.; Deliliers, G.L.; Ghidoni, R. In vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br. J. Haematol., 2009, 144(3), 350-357.
282. Ricci, C.; Onida, F.; Ghidoni, R. Sphingolipid players in the leukemia arena. Biochim. Biophys. Acta, 2006, 1758(12), 2121-2132.
283. Itoh, M.; Kitano, T.; Watanabe, M.; Kondo, T.; Yabu, T.; Taguchi, Y.; Iwai, K.; Tashima, M.; Uchiyama, T.; Okazaki, T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res., 2003, 9(1), 415-423.
284. Neviani, P.; Santhanam, R.; Oaks, J.J.; Eiring, A.M.; Notari, M.; Blaser, B.W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti- Passerini, C.; Druker, B.J.; Cortes, J.; Marcucci, G.; Chen, C.S.; Verrills, N.M.; Roy, D.C.; Caligiuri, M.A.; Bloomfield, C.D.; Byrd, J.C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117(9), 2408-2421.
285. Lahiri, S.; Park, H.; Laviad, E.L.; Lu, X.; Bittman, R.; Futerman, A.H. Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner. J. Biol. Chem., 2009, 284(24), 16090-16098.